These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36342223)

  • 1. A cost-effectiveness analysis of pharmacotherapy versus prostatic urethral lift as initial therapy for patients with moderate benign prostatic hyperplasia.
    Tung JY; Aslim EJ; Ho HS; Chen C
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):63-68. PubMed ID: 36342223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore.
    Chay J; Tung JYM; Su RJ; Aslim EJ; Wong C; Swan G; Chua WJ; Ho HSS; Finkelstein EA
    J Med Econ; 2023; 26(1):1269-1277. PubMed ID: 37800562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study.
    Sahakyan Y; Erman A; Bhojani N; Chughtai B; Zorn KC; Sander B; Elterman DS
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):113-118. PubMed ID: 35689083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan's public healthcare system.
    Anezaki H; Endo F; Swan G; Takashima K; Rojanasarot S
    J Med Econ; 2024; 27(1):554-565. PubMed ID: 38466193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Minimally Invasive Procedures for Benign Prostatic Hyperplasia: A Cost-effectiveness Analysis.
    Wu X; Zhou A; Heller M; Chi T; Kohlbrenner R
    Radiology; 2023 Dec; 309(3):e230555. PubMed ID: 38085076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis.
    Wei Y; Hay JW; Hay AR; Suen SC
    BMC Urol; 2022 May; 22(1):76. PubMed ID: 35550071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.
    Erman A; Masucci L; Krahn MD; Elterman DS
    BJU Int; 2018 Nov; 122(5):879-888. PubMed ID: 30113127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility of minimally invasive therapies vs. pharmacotherapy as initial therapy for benign prostatic hyperplasia A Canadian healthcare payer perspective.
    Sahakyan Y; Erman A; Bhojani N; Chughtai B; Zorn KC; Sander B; Elterman DS
    Can Urol Assoc J; 2023 Apr; 17(4):103-110. PubMed ID: 36486181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia.
    Chughtai B; Rojanasarot S; Neeser K; Gultyaev D; Amorosi SL; Shore ND
    J Health Econ Outcomes Res; 2021 May; 8(1):42-50. PubMed ID: 33987450
    [No Abstract]   [Full Text] [Related]  

  • 10. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia.
    Chughtai B; Rojanasarot S; Neeser K; Gultyaev D; Fu S; Bhattacharyya SK; El-Arabi AM; Cutone BJ; McVary KT
    PLoS One; 2022; 17(4):e0266824. PubMed ID: 35427376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia.
    Roehrborn CG; Rukstalis DB
    Eur Urol Focus; 2022 Jan; 8(1):217-227. PubMed ID: 33436276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis.
    Perera M; Roberts MJ; Doi SA; Bolton D
    Eur Urol; 2015 Apr; 67(4):704-13. PubMed ID: 25466940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.
    Udeh EI; Ofoha CG; Adewole DA; Nnabugwu II
    BMC Cancer; 2016 Jul; 16():405. PubMed ID: 27388750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urethral lift for benign prostatic hyperplasia: a comprehensive review of the literature.
    Larcher A; Broglia L; Lughezzani G; Mistretta F; Abrate A; Lista G; Fossati N; Sangalli M; Kuefner D; Cestari A; Buffi N; Lazzeri M; Guazzoni G; Montorsi F
    Curr Urol Rep; 2013 Dec; 14(6):620-7. PubMed ID: 23794125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
    Walker A; Doyle S; Posnett J; Hunjan M
    BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.
    Bjerklund Johansen TE; Baker TM; Black LK
    BJU Int; 2012 Mar; 109(5):731-8. PubMed ID: 21933326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study.
    Roehrborn CG; Gange SN; Shore ND; Giddens JL; Bolton DM; Cowan BE; Brown BT; McVary KT; Te AE; Gholami SS; Rashid P; Moseley WG; Chin PT; Dowling WT; Freedman SJ; Incze PF; Coffield KS; Borges FD; Rukstalis DB
    J Urol; 2013 Dec; 190(6):2161-7. PubMed ID: 23764081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
    Woo HH; Chin PT; McNicholas TA; Gill HS; Plante MK; Bruskewitz RC; Roehrborn CG
    BJU Int; 2011 Jul; 108(1):82-8. PubMed ID: 21554526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study.
    Sønksen J; Barber NJ; Speakman MJ; Berges R; Wetterauer U; Greene D; Sievert KD; Chapple CR; Montorsi F; Patterson JM; Fahrenkrug L; Schoenthaler M; Gratzke C
    Eur Urol; 2015 Oct; 68(4):643-52. PubMed ID: 25937539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.